Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

Aprea Therapeutics, a US-based cancer drug developer backed by healthcare provider Praktikertjänst, has raised $85m yesterday in an initial public offering on the Nasdaq Global Select Market. The company issued approximately 5.7 million shares on Tuesday priced at $15 each, in the middle of the IPO’s $14 to $16 range. Its shares rose by more…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.